Prawo i regulacje · 16/11/2015

Eluxadoline Schedules Placement into Schedule IV by DEA

The U.S. Drug Enforcement Administration (DEA) has announced the placement of Eluxadoline into Schedule IV of the Controlled Substances Act, a change that affects the medication's availability and regulation. This decision will impact pharmaceutical companies and healthcare providers who use Eluxadoline for treating chronic constipation.